secwatch.observer — SEC 8-K summary
======================================

Issuer:     MiNK Therapeutics, Inc. (INKT)
CIK:        0001840229
Form:       8-K
Filed at:   2026-08-13T11:40:44+00:00
Accession:  0001193125-26-347907
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MiNK Q2 2026 net loss $3.1M, cash $8.8M; Phase 2 ALI data positive
------------------------------------------------------------------

- Net loss $3.1M ($0.62/share) vs $4.2M ($1.06) in Q2 2025; six-month loss $5.9M vs $7.0M.
- Cash $8.8M at June 30, 2026, down from $9.5M at March 31 and $13.4M at Dec 31, 2025.
- Randomized Phase 2 (C-1300-02) in acute lung injury: first patients alive at Day 28, improved oxygenation, infection control, ventilator/vasopressor liberation; no major SAEs.
- Established first paid international named-patient access program in Brazil via Orphan Drug Consulting for agenT-797.
- Data presented at MHSRS; U.S. expansion underway, more data expected early 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840229/000119312526347907/0001193125-26-347907-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840229/000119312526347907/inkt-20260813.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-347907

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer